Oliver Kahl - Profile and Investment Details

Investor Profile

Oliver Kahl is a Venture Capital, University Program, Incubator, Entrepreneurship Program, Accelerator, Private Equity Firm, Venture Debt based in Munich, Bavaria, Germany with a diverse investment portfolio that includes companies such as Siltectra, Hemovent, AFFiRiS, KEWAZO, Corimmun, PartechGWA Hygiene, immatics biotechnologies, BioNTech, IDENT Technology, NcodiN, Pixel Photonics, Protagen, Sovicell GmbH, Biocrates Life Sciences, NavVis, talpasolutions, iThera Medical GmbH, Second Closet, advanceCOR, Isarna Therapeutics, Ganymed Pharmaceuticals, Look Up Space, Liva Healthcare, NFON, KONUX, AMSilk, German Bionic, LXP Group GmbH, SuppreMol, IQM, PDC Biotech, Efficient Energy, InBolt, Innatera Nanosystems, Jobachem GmbH, Cynora, . Over time, Oliver Kahl has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Oliver Kahl is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Commercial, Wearables, Customer Service, Disruptive Innovation, Wellness, Design, Transportation, Apps, Energy, Strategic Partnerships, Chemical, Life Science, Lighting, Education, Artificial Intelligence (AI), Robotics, Startups, Analytics, Venture Fundraising, Business Development, Technology, Software, Manufacturing, Biotechnology, Construction, Open Source, Commerce, Clean Technology, Entrepreneurship, Materials, Innovation, FinTech, Disruptive technology, Natural Language Processing, Space Technology, Capital Raising, Colleges, Hardware, Logistics, Technology Transfer, Health Diagnostics, Social Impact, Digital Health, Medical, Information Technology, B2B, Health Tech, Media and Entertainment, Quantum Computing, Recycling, Risk Management, Web3 may find it worthwhile to explore potential connections with Oliver Kahl, as their portfolio suggests a familiarity and interest in this area.

Understanding Oliver Kahl’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.